Themis Medicare Approves ₹0.50 Dividend, Appoints New Independent Director and Secretarial Auditor
The dividend payout provides direct returns to shareholders. The appointment of an experienced independent director can enhance strategic decision-making and governance, while a new secretarial auditor ensures compliance, collectively having a medium positive impact on the company's operational and governance structure.
The declaration of a dividend is positive for shareholders, and the appointment of an experienced independent director and a secretarial auditor strengthens corporate governance and oversight.
* The members of Themis Medicare Limited have approved a dividend of Re. 0.50, i.e., 50% per equity share with a face value of Re.1/- each, for the Financial Year ended 31st March, 2025. This aggregates to ₹4,60,20,060. * M/s. SAV & Associates LLP, Practicing Company Secretaries, represented by CS Shirish Shetye, has been appointed as the Secretarial Auditor for a term of five consecutive financial years, commencing from the financial year ending 31st March, 2026, up to 31st March, 2030. * Ms. Neha Thakore (DIN: 00893957) has been appointed as an Independent Woman Director of the Company with effect from 1st August, 2025, till 31st July, 2030. She will not be liable to retire by rotation. * Ms. Neha Thakore is a graduate in Social Science and a seasoned leader in the pharmaceutical industry with over 25 years of experience in the Active Pharmaceutical Ingredients (API) business. She currently serves as the Managing Partner of Rifa Pharma and Chief Operating Officer & Director at Avik Pharmaceutical Ltd. Her expertise includes business development, operations management, and international regulatory affairs, and she contributes to industry development through various committee positions.
What to do with a filing like this
Themis Medicare Limited filed this with the NSE as a statutory disclosure, categorised under corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Themis Medicare Limited. Read the original for the full detail.